دورية أكاديمية
Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases
| العنوان: | Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases |
|---|---|
| المؤلفون: | Faivre, Coline, Villani, Axel Patrice, Aubin, François, Lipsker, Dan, Bottaro, Martine, Cohen, Jean-David, Durupt, François, Jeudy, Géraldine, Sbidian, Émilie, Toussirot, Eric, Badot, Valérie, Barbarot, Sébastien, Debarbieux, Sebastien, Delaporte, Emmanuel, Goegebeur, Guetty, Morel, Jacques, Nassif, Aude, Duru, Gérard, Jullien, Denis, Club Rheumatisms And Inflammation, French Society of Dermatology And |
| المساهمون: | Hôpital Edouard Herriot CHU - HCL, Hospices Civils de Lyon (HCL), Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté COMUE (UBFC)-Université Bourgogne Franche-Comté COMUE (UBFC), Centre Hospitalier Universitaire Strasbourg (CHU Strasbourg), Les Hôpitaux Universitaires de Strasbourg (HUS), Centre hospitalier de Valence, Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de dermatologie Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre d'Investigation Clinique de Besançon (Inserm CIC 1431), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang Bourgogne-Franche-Comté (EFS BFC)-Université de Franche-Comté (UFC), Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital Erasme Bruxelles (ULB), Faculté de Médecine Bruxelles (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Service de dermatologie Nantes, Université de Nantes (UN)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Centre Hospitalier Lyon Sud CHU - HCL (CHLS), Hôpital Claude Huriez Lille, Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Loire Vendée Océan, Département de Rhumatologie Montpellier, Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Hôpital Lapeyronie, Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Département de Pédiatrie et maladies infectieuses CHU Necker, Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d'infectiologie Necker-Pasteur CHU Necker, Institut Pasteur Paris (IP)-Hôpital Necker - Enfants Malades AP-HP, Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur Paris (IP) |
| المصدر: | ISSN: 0190-9622. |
| بيانات النشر: | HAL CCSD Elsevier |
| سنة النشر: | 2016 |
| المجموعة: | Université de Nantes: HAL-UNIV-NANTES |
| مصطلحات موضوعية: | paradoxical reactions, tumor necrosis factor-alfa inhibitors, biologic agents, hidradenitis suppurativa, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology |
| الوصف: | International audience ; BACKGROUND:Paradoxical hidradenitis suppurativa (HS) induced by biologic agents (BA) is scarcely reported.OBJECTIVE:We sought to describe the clinical characteristics and outcome of patients developing paradoxical HS under BA.METHODS:This was a multicenter nationwide retrospective study asking physicians to report all cases of HS, confirmed by a dermatologist, occurring during treatment of an inflammatory disease by a BA.RESULTS:We included 25 patients (15 inflammatory rheumatism, 9 Crohn's disease, 1 psoriasis) treated by 5 BA (adalimumab = 12, infliximab = 6, etanercept = 4, rituximab = 2, tocilizumab = 1). Median duration of BA exposure before HS onset was 12 (range 1-120) months. Patients were mostly Hurley stage I (n = 13) or II (n = 11). Simultaneously to HS or within 1 year, 11 patients developed additional inflammatory diseases, including paradoxical reactions (psoriasis = 9, Crohn's disease = 3, alopecia areata = 1, erythema elevatum diutinum = 1). Complete improvement of HS was more frequently obtained after BA discontinuation or switch (n = 6/10, 60%) rather than maintenance (n = 1/14, 7%). Reintroducing the same BA resulted in HS relapse in 3 of 3 patients.LIMITATIONS:Retrospective nature and lack of complete follow-up for some patients are limitations.CONCLUSION:HS is a rare paradoxical adverse effect of BA, but fortuitous association cannot be excluded in some cases. We observed a trend toward better outcome when the BA was discontinued or switched. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/26965410; hal-01873018; https://hal.science/hal-01873018Test; PUBMED: 26965410 |
| DOI: | 10.1016/j.jaad.2016.01.018 |
| الإتاحة: | https://doi.org/10.1016/j.jaad.2016.01.018Test https://hal.science/hal-01873018Test |
| رقم الانضمام: | edsbas.40B297A4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.jaad.2016.01.018 |
|---|